Cotellic
Active Ingredient(s): CobimetinibFDA Approved: * November 10, 2015
Pharm Company: * GENENTECH INC
Category: Cancer
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Cotellic Overview
Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech (Roche). It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.[4] Contents 1 Me...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cobimetinib
Recent Cotellic Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Cobimetinib
- Tablet: 20mg
NDC Database Records for Cotellic: (1 result)
Sorted by National Drug Code- 50242-717 Cotellic 20 mg Oral Tablet, Film Coated by Genentech, Inc.